Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Phase 1/2
104
about 2.6 years
18+
1 site in NC
About this study
Researchers are testing the best dose of a treatment for people with advanced basal-like pancreatic cancer. The goal is to see if this combination of drugs is safe, effective, and well-tolerated in these patients. The trial will also follow some patients with classical subtypes who are treated per standard of care on oxaliplatin-based triplet chemotherapy.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Erlotinib
- 2.Take Folfirinox
- 3.Take Gemcitabine
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
erlotinib, chemotherapy, gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
oral (Oral Tablet), infusion, injection (Injection)
Primary: Adverse Events per Common Terminology Criteria for Adverse Events (NCI-CTCAE), Dose-limiting toxicity (DLT), Overall survival- classical metastatic pancreatic adenocarcinoma, Progression-free survival
Secondary: Overall survival in subjects with basal-like metastatic pancreatic adenocarcinoma, Progression-free survival (PFS) in subjects with classical pancreatic adenocarcinoma, The number of Adverse Events (AEs) in subjects with basal like pancreatic carcinoma, The number of Adverse Events (AEs) in subjects with classical pancreatic adenocarcinoma, The objective response in subjects with classical pancreatic adenocarcinoma, The objective response rate- basal-like pancreatic carcinoma
Oncology